Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 20 Aug 2025
Mental health providers are trained to guide others through trauma, yet their own exposure to clients' suffering can take a significant toll. Studies show that between 40% and 85% of providers experience compassion fatigue ...
Read Full NewsAripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.
Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.
In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Lung Transplant for Lung Cancer: Promising, in Rare Cases
3.
Rural-urban disparities seen in cervical cancer
4.
Obesity linked to subsequent neoplasms in childhood cancer survivors
5.
New policy review highlights the importance of health-related quality of life in advanced cancer
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
3.
Is AI The New Radiologist For Breast MRI?
4.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
5.
Bone Marrow Regeneration in Hematologic Recovery
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge